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The PC functional domains governing its interactions with 
Abstract Protein C (PC) is a vitamin K-dependent zymogen other macromolecular components of the protein C protein S 
that inactivates factors Va and VIIla after its activation by system remain to be identified. EGF-like domains have been 
thrombin complexed to thrombomodulin. We characterized a implicated in its interaction with protein S [13], factors Va and 
monoclonal antibody (mAb) against PC, whose only influence on 
PC functions was to inhibit PC activation by the thrombin- VIIIa [16], and the thrombin-thrombomodulin complex in as- 
thrombomodulin complex. It recognized an epitope in the PC sociation with the Gla domain [17]. Mesters et al. [18] demon- 
heavy chain, the conformation of which is calcium-dependent. The strated that the sequence corresponding to amino acids 142- 
mAb did not recognize a natural PC variant that was not acti- 155 of the human PC light chain was a factor Va-binding site. 
vated by the thrombin-thrombomodulin complex (mutation In the heavy chain, two other domains have been shown to 
R229Q) and did recognize a synthetic peptide corresponding to interact with macromolecules: the sequence corresponding to
PC amino acids 225-235 in an Elisa assay. The peptide inhibited residues 311 325 is required for factor Va binding [19], and the 
PC activation by the thrombin-thrombomodulin complex. These sequence corresponding to residues 390404 is required for 
data confirm that the calcium-binding loop of the serine-protease factor Va and/or VIIIa binding [20]. 
domain is involved in the interaction of PC with the thrombin- Monoclonal antibodies (mAb) are useful tools to analyse 
thrombomodulin complex, protein functional domains [21,22,23]. Among 10 monoclonal 
Key words." Protein C; Activation; Monoclonal antibody; antibodies directed against human protein C, we selected one 
Thrombin thrombomodulin complex which specifically inhibited protein C activation by the throm- 
bin thrombomodulin complex. The location of its epitope in 
the domain encompassing amino acids 225 235 suggests that 
thrombomodulin interacts with the heavy chain of protein C, 
1. Introduction at the site involved in its high affinity for calcium. 
Protein C is a vitamin K-dependent zymogen [1], which is 2. Materials and methods 
activated on the endothelial cell surface by thrombin com- 
plexed to thrombomodulin [2,3]. In the presence of its nonenzy- 2.1. Reagents 
matic cofactor protein S, activated protein C inactivates factors Protein C, thrombin and substrate CBS-4246 were from Diagnostica 
Va and VIIIa by limited proteolysis [4,5], and is thus a potent Stago (Asni+res, France), hirudin was from Ciba-Geigy (Bfile, Switzer- 
land), heparin was from Choay (Sanofi, France) and substrate S-2366 
anticoagulant [6]. was from Chromogenix (Montpellier, France). Activated human pro- 
Protein C consists of a light chain (Mr 21,000), which con- tein C was purified by pseudo-affinity chromatography [24]. 
tains the Gla domain (nine y-carboxyglutamic acids) and two Horseradish peroxidase-labelled rabbit anti-human PC polyclonal 
domains homologous to the epidermal growth factor (EGF) immunoglobulin was obtained from Dako SA (Trappes, France) and 
precursor (EGF-like domains), and a heavy chain (Mr 41,000) rabbit thrombomodulin from American Diagnostica (Greenwich, 
USA). Horseradish peroxidase-labelled rabbit anti-mouse IgG polyclo- 
linked to the light chain by a single disulfide bond and contain- nal immunoglobulin and bovine serum albumin (BSA) were from 
ing the serine protease domain [7]. Sigma Chimie (St. Quentin Fallavier, France). 
Calcium ions are known to play an important role in the Monoclonal antibodies and the synthetic peptide were prepared by 
activation and physiological ctivity of protein C [8,9]. Calcium bioM6rieux (Marcy-l'Etoile, France). 
binding to the Gla domain is required for membrane associa- 2.2. Preparation of monoclonal ntibodies 
tion [10,11,12] and the first EGF-like domain may be involved Murine monoclonal antibodies (mAb) were selected, isolated and 
in high-affinity calcium binding [13]. Recently, another high- characterized essentially asdescribed [25]. The subclass was determined 
affinity calcium-binding site has been located in the serine pro- with a commercial kit (Clonotyping System III, Fisher, Pittsburgh, PA) 
tease domain [14]; this site is involved in protein C activation as IgG1. MAbs were purified from ascitic fluid by means of protein 
G-Sepharose affinity chromatography (Pharmacia LKB Biotechnol- 
by the thrombin-thrombomodulin complex [15]. ogy). 
2.3. Immunoblotting for protein C 
*Corresponding author. Fax: (33) (1) 4407-1772. Samples containing 10/al of purified protein C or activated purified 
protein C (0.2/aM) were electrophoresed on 5% stacking and 12% 
**The numbering used in this manuscript corresponds to the amino separating polyacrylamide slab gels in the presence of sodium do- 
acid sequence ofmature single-chain protein C. decylsulfate (SDS-PAGE) according to Laemmli [26], and with 4% 
fl-mercaptoethanol when reduction was required. Protein was trans- 
Abbreviations: PC, protein C; mAb, monoclonal ntibody; APC, acti- ferred onto a nitrocellulose membrane, using the Bio-Rad Minisystem 
vated protein C; Ig, immunoglobulin. (Ivry-sur-Seine, France). The blot was treated as recommended by the 
0014-5793/95/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
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manufacturer, made to react with the mAb (20 nM), thoroughly The plates were coated with 120 fll of 25/2M peptide in sodium 
washed, and incubated with a 1 : 1000 dilution of alkaline phosphatase- carbonate buffer and blocked with 4% BSA in PBS buffer. Monoclonal 
conjugated goat anti-mouse IgG (Bio-Rad) before revelation, antibodies were diluted from 20 nM to 2.5 nM and incubated in a 
volume of 100 pl for 1 h at 20°C. Bound mAb was determined by 
2.4. Plasma assay for protein C adding 100plofhorseradishperoxidase-labelled rabbitanti-mouselgG 
The hereditary protein C abnormality was diagnosed by three types polyclonal immunoglobulin diluted 1 : 1000. After 1 h of incubation, 
of assays: immunoenzymatic (Asserachrom Protein C, Diagnostica bound antibodies were quantified as described above. 
Stago, Asni6res, France), amidolytic (Berichrom Protein C, Behring, 2.5.4. Inhibition of PC activation by the thrombin-thrombomodulin 
Rueil-Malmaison, France), and coagulation (Staclot Protein C, Diag- complex in the presence ofpeptide 225-235. PC was activated by the 
nostica Stago), all performed as recommanded by the manufacturers, thrombin thrombomodulin complex in the presence of peptide 225 
In the amidolytic and coagulation assays, plasma protein C was acti- 235, as described above. The peptide (04).54/.tM) was incubated for 15 
vated by Protac snake venom. Once activated, it was made to react with min at 37°C with thrombin thrombomodulin (0.03(~7.5 U/ml) com- 
a synthetic hromogenic substrate in the amidolytic assay and in the plex before the addition of PC (0.22 pM). 
coagulation assay, with a natural substrate, i.e. plasma depleted in 
protein C as a source of factor V, factor VIII, and protein S in the 
presence of cephaline and calcium [28]. 3. Results 
Protein C activity was also evaluated after activation by the throm- 
bin thrombomodulin complex according to Sala [30]. Briefly, 1 ml of 3.1. Characterization ofmonoclonal antibody 12HI2F s directed 
plasma was treated with 80/.tl of 1 M BaC12, 0.3 M Tris, pH 8, at 4°C against human protein C 
for 30 min. The precipitate obtained was washed with buffer 50 mM Among the 10 mAbs tested, 12H12F5 was the only one with 
Tris, 100 mM NaC1, pH 7.4, and eluted by 250pl of 0.15 mM trisodium 
citrate, pH 7.5. The eluate was then added with thrombin (10 U/ml)- a selective inhibitory effect on the activation of protein C by 
thrombomodulin (4.5 U/ml) complex (9: 1) and allowed to react for 60 thrombin - thrombomodul in  complex. 12H~2F5 mAb did not in- 
min at 37°C. The reaction was stopped by adding the same volume of terfere with the activation of protein C by thrombin alone and 
hirudin (10 U/ml) and amidolytic activity of the activated protein C did not inhibit the amidolytic or ant icoagulant activity ofpreac- 
generated was measured by monitoring hydrolysis of the substrate 
CBS-4246 (1.25 mM) at 405 nm for 60 min. tivated protein C (data not shown). This mAb recognized both 
forms of protein C (zymogen and activated) and bound the 
2.5. Effects of l2Hi2F 5 mAb on protein C functions heavy chain in reducing conditions (not shown). 
2.5.1. Protein Cactivation. The effect of the monoclonal ntibodies Fig. 1 clearly shows that the inhibit ion of protein C activa- 
on protein C activation was analyzed after incubating protein C with tion by thrombin - thrombomodul in  complex was concentra- 
the mAb (ratio 1 : 0 to 1 : 8) for 15 min prior to activation. Protein C tion-dependent. 
(0.22 pM) was then activated for 30 min at 37°C with human thrombin 
(1.8 U/ml) in buffer A (20 mM Tris-HC1, 0.15 M NaCl, pH 7.0) or for As PC has been shown to undergo calcium-induced confor- 
2 h with a human thrombin (0.036 U/ml)-rabbit thrombomodulin (7.5 mational  changes required for activation by the thrombin -  
U/ml) complex in buffer A containing 2.5 mM CaC12. The reaction was thrombomodul in  complex [29], we evaluated the calcium de- 
stopped by adding 10 pl hirudin (200 U/ml). The amidolytic activity of pendence of PC recognition by the mAb. As shown in Fig. 2, 
the activated protein C (APC) thus generated was measured by moni- 
toring hydrolysis of the substrate S-2366 (Glu-Pro-Arg-pNA) (0.6 mM) 12HIzF5 binding to protein C was more efficient in the absence 
at 405 nm for 15 min. of calcium than in its presence. 
The effect of the monoclonal antibodies on APC amidolytic activity 
was tested as follows: APC was completely activated with human 
thrombin and then incubated with the mAb for 15 min at 37°C. Throm- 
bin was then inhibited by hirudin and absorbance was measured at 
405 nm for 15 min after adding S-2366. 
2.5.2. APC anticoagulant activity. This experiment was adapted Inhibition (%) 
from the APC-resistance t st [27]. 
Fifty/~1 of a pool of normal plasmas was incubated with 50 ,ul of 80 
APTT (Organon-Technika) at 37°C for 3 min. Clotting was initiated 
by adding 50 pl of a mixture of APC (25.6 nM), CaCI2 and mAb 
(100 nM). The clotting time was measured on a ST4 analyser (Diagnos- 60 
tica Stago). 
2.5.3. Enzyme-linked immunosorbent assay ( Elisa ) . 
(a) Recognition of plasma PC by mAbs. Polystyrene microtiter plates 
(MaxiSorp, Immuno Nunc, Roskilde, Denmark) were coated overnight 40 
at 4°C with 130 pl of l 0 pg/ml mAb in 50 mM sodium carbonate buffer, 
pH 9; the plates were then washed thrice in PBS-Tween buffer and 
blocked with 2% bovine serum albumin in buffer A for 2 h at room 20 
temperature. A pool of normal control plasmas and a plasma sample 
from a patient heterozygous for mutation R229Q [28] were diluted 1 : 5 
to 1:40 in buffer A. The samples were incubated in a volume of 100 0 . . . .  
p l  for 2 h at room temperature. After 3 washings, bound protein C was 0 2 4 6 8 
measured by adding 100 pl of horseradish peroxidase-labelled rabbit 
anti-human PC polyclonal immunoglobulin diluted 1 : 1000. After one 12H12F5/PC ratio 
hour of incubation at room temperature, 100pl of o-phenylene diamine 
(substrate) was added and the reaction was stopped 30 min later by Fig. 1. Effect of mAB 12HIzF5 on PC activation by thrombin-throm- 
adding 50 pl of 1 M H2SO 4. Absorbance was measured at 490 nm on bomodulin complex. PC (0.22/tM) was activated by thrombi~throm- 
a microplate reader (Dynatech MR 5000, Saint Cloud, France). bomodulin (0.036 7.5 U/ml) complex in the presence of 2.5 mM cal- 
(b) Recognition ofpeptide 225-235 (Glu-Tyr-Asp-Leu-Arg-Arg-Trp- cium chloride and increasing mAb concentrations. The reaction was 
Glu-Lys-Trp-Glu). The specificity of 12H~2F 5 for the peptide was eval- stopped with hirudin and amidolytic activity was measured by the 
uated by studying mAb binding to the immobilized peptide in the hydrolysis of the substrate S-2366. Results are the mean of 3 experi- 
ELISA assay, by comparison with a control mAb, 2EzAsD2, which ments. The graph represents he percentage (%)inhibition of PC activa- 
inhibits PC activation by both thrombin and the thrombin throm- tion by thrombin thromhomodulin complex versus the PC:mAb ratio 
bomodulin complex. (1:0 to 1:8). 
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A 490rim 3.4. Inhibition of PC activation by peptide 225~35 
1,2 PC activation by the thrombin-thrombomodulin complex 
was inhibited by the peptide in a concentration-dependent ma -
1,0 | her (Fig. 5). 
These results support the location of a thrombin throm- 
bomodulin complex binding site in the region containing amino 
0,8 acids 225 235 of the PC serine-protease domain. 
0,6 4. Discussion 
Previous tudies with protein C lacking the Gla domain have 
0,4 identified a high-affinity, Gla-independent calcium-binding site 
within the serine-protease domain [14]. Calcium binding to this 
0,2 site elicits a conformational change that could play a critical 
role in PC activation. Rezaie et al. [15] demonstrated that, when 
[ [ PC Glu-235 was replaced by Lys, calcium ions were no longer 
0,0 | I required for optimal activation by the thrombin thrombomod- 
EDTA = 5 mM Ca2+ = 10 mM ulin complex, showing that Glu-235 was involved in the cal- 
Fig. 2. Effect of CaCI2 concentration protein C binding to 12H~zFs. cium-dependent conformation. 
MAb 12H12F5 (10 pg/ml) was coated on wells of microtiter plates by Modelling studies have suggested that this high-affinity cal- 
overnight incubation i  50 mM sodium carbonate buffer, pH 9.0. After cium-binding site is located in amino acid domain 225 235 
washings, protein C (100/~1 of normal plasma diluted 1:40) was incu- corresponding to the trypsin calcium-binding loop; three acidic 
bated for 1 hour at room temperature in the presence of5raM EDTA 
or 10 mM CaCI2 and 2000 UI/1 hirudin in 20 mM Tris, 0.15 M NaCI .  residues within this region were thought to be crucial: Glu-225, 
Bound protein C was measured as described in section 2. The results 232 and 235, which carboxylate oxygen could ligate calcium 
are the mean (+ S.D.) of six experiments. [31,32]. 
Monoclonal antibodies against human PC have been used to 
study conformational changes [21,22]. Using this approach, we 
characterized a calcium-dependent monoclonal antibody to 
3.2. Binding of 12H12F5 to PC in the plasma of  a patient human PC, 12HlzFs, which binds to the heavy chain and only 
heterozygous for the Arg-229 to Gin mutation blocks PC activation by the thrombin-thrombomodulin com- 
The patient carying the Arg-229 to Gin mutation belongs to plex (no effect on PC activation by thrombin, or on the ami- 
a family having a qualitative deficiency previously described dolytic and anticoagulant activities of PCa). 
[28]. Protein C concentration was 100% in an immuno-assay 
using a polyclonal antibody. Protein C activity after activation A 490 nm 
by the Protac was 96% in an amidolytic assay, and 57% in a 
coagulation assay. Protein C activity after activation by the 1,5 
thrombin-thrombomodulin complex was 44% (see section 2). 
These data point to a role of Arg-229 in the activation of 
protein C by thromhin in the presence of thrombomodulin. 
A pool of normal plasmas and the patient's plasma were 
made to react with the mAb in microtiter plates and the amount 1,0 
of bound protein C was measured. As shown in Fig. 3, 12Ht2F 5 
bound to the patient's protein C less efficiently than to normal 
plasma PC. The patient plasma PC concentration measured 
with this monoclonal ntibody based assay was 50%, showing 
that half the patient plasma PC molecules were not recognized 
by 12HIzFs. Since the patient was heterozygous, this indicate 0,5 
that the PC molecules bearing the Arg-229 to Gln mutation 
were not recognized by 12HlzF 5. 
3.3. Binding of 12H1:F5 to peptide 225~35 
We used a synthetic peptide to confirm that 12HI2F 5 binds 0,0 , 
to an epitope absent from the mutated protein C. The peptide 0 20 40 60 80 I00 120 
consisted of amino acids 225 235 of human PC, which are Protein C concentration (%) 
involved in the interaction of calcium with the serine-protease Fig. 3. Comparison of the binding curves of normal and mutant 
domain. Recognition of the peptide by the mAb 12HIzF 5 was (R229Q) protein C to mAb 12H~zF ~.12Ht2F 5was coated on the wells 
concentration-dependent (Fig. 4), whereas the control mAb of microtiter plates as described insection 2. The wells were incubated 
2E2AsD2, which inhibits PC activation by both thrombin and with various dilutions of normal (A) or R229Q mutant (m) protein C 
(dilution 1 : 10 corresponding to 100%) in 20 mM Tris, 0.15 M NaCI. 
thrombin-thrombomodulin complex, did not recognize the Bound protein C was measured asdescribed above. The results are the 
peptide. The 12H~2F5 epitope is thus at least partly located mean (+ S.D.) of six experiments. The graph represents the absorbance 
within the amino acid domain 225 235. at 490 nm (A490 ,m) versus the protein C concentration (%). 
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Optimal binding of 12H~2F5 to the heavy chain in the absence Inhibition (%) 
of calcium, and the sole inhibitory effect on protein C activation 120 - 
by the thrombin-thrombomodulin complex, suggested that the 
epitope was located in the putative calcium-binding loop. 
To characterize the 12H12F5 mAb epitope, we used plasma 100- 
from a patient who is heterozygous for the mutation Arg-229 
to Gln. This mutated PC, characterized by reduced anticoagu- 80 - 
lant activity and normal amidolytic activity, was not activated 
by the thrombin-thrombomodulin complex, whereas activa- 
tion by Protac was normal [28]. Residue Arg-229 is located 60" 
within the high-affinity calcium-binding loop. Substitution of 
Arg-229 abrogates both anticoagulant activity and PC activa- 40- 
tion by the thrombin thrombomodulin complex, confirming 
the functional importance of this region for PC activity [31]. 
12HlzF 5 mAb did not recognize the mutated PC, indicating 20 - 
that Arg-229 is required for the binding of protein C to 12HI2F5 
and is included within the epitope. Moreover, the reduced bind- 0 
ing of the mAb to PC in the presence of calcium suggested that 
0,0 0,1 0,2 0,3 0,4 0,5 0,6 
it recognized the calcium-binding loop. This was confirmed by 
the use of a synthetic peptide comprising residues 225-235 of Peptide concentration [laM] 
human protein C (Glu-Tyr-Asp-Leu-Arg-Arg-Trp-Glu-Lys- Fig. 5. Effect of peptide 225-235 on PC activation by the thrombin- 
Trp-Glu). In the ELISA method, the mAb recognized this pep- thrombomodulin complex. Increasing concentrations of peptide 
tide in a concentration-dependent manner, whereas another (0~0.54/iM) were incubated for 15 min at 37°C with thrombin throm- 
bomodulin complex in the presence ofcalcium ions. PC (0.22/tM) was 
mAb (2E2A8D2), which inhibited PC activation by both throm- then activated by this mixture as described inFig. 1. The results are the 
bin and thrombin-thrombomodulin complex, did not. mean of three xperiments. The graph represents percentage inhibition 
The intact Gla-EGF fragment has been reported to inhibit of protein C activation versus peptide concentration [aM]. 
PC activation [17]. The properties of 12H12Fs, which recognized 
the calcium-binding loop and only inhibited PC activation by 
the thrombin-thrombomodulin complex, together with the site of the serine-protease domain is involved in PC activation 
characteristics of PC with Arg-229 to Gin [28] and Glu-235 to by the thrombin-thrombomodulin complex. 
Lys mutations [15], show that the high-affinity calcium-binding We thus explored the effect of the synthetic peptide 225-235 
on PC activation by the thrombin-thrombomodulin complex. 
As expected, the peptide inhibited activation in a concentra- 
A 490 nm tion-dependent manner. Inhibition was complete with peptide 
1,0 concentrations over 0.54/.tM (peptide: PC ratio = 4000: 1). 
In conclusion, anti-protein C monoclonal ntibody 12H12F5 
did not bind the PC mutant R229Q, which is not activated by 
0,8 the thrombin-thrombomodulin complex, and recognized the 
serine-protease domain calcium-binding loop. Moreover, it 
only inhibited PC activation by the thrombin-thrombomodulin 
0,6 complex. The synthetic peptide 225-235, which encompasses 
the mAb 12H~2F5 epitope, also inhibited PC activation by the 
complex. These results provide direct evidence that the throm- 
0,4 bin-thrombomodulin complex interacts with amino acid se- 
quence 225-235 of human protein C. Further experiments with 
different peptides and/or PC mutants are necessary to deter- 
0,2 mine the exact role of each residue of the loop in calcium and/or 
thrombomodulin binding. 
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